Dashboard
Manage Tickers

SUPN


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

adhd-drug-maker-supernus-pharmaceuticals-downgraded-on-slower-prescription-growth-for-its-top-selling-drug
ADHD Drug Maker Supernus Pharmaceuticals D...
09/11/2024 18:38:19

Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in Qelbree prescriptions during back-to-sc...

this-novartis-analyst-is-no-longer-bullish-here-are-top-downgrades-for-wednesday
This Novartis Analyst Is No Longer Bullish...
09/11/2024 16:13:54

dominos-pizza-to-510-here-are-10-top-analyst-forecasts-for-wednesday
Domino's Pizza To $510? Here Are 10 Top An...
09/11/2024 13:08:03

piper-sandler-downgrades-supernus-pharmaceuticals-to-neutral-lowers-price-target-to-36
Piper Sandler Downgrades Supernus Pharmace...
09/11/2024 10:41:02

Piper Sandler analyst David Amsellem downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) from Overweight to Neutral and lowers...

fda-accepts-supernus-pharmaceuticals-resubmission-for-parkinsons-treatment-device-decision-expected-by-february-2025
FDA Accepts Supernus Pharmaceuticals' Resu...
08/19/2024 11:03:06

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products fo...

supernus-pharmaceuticals-shares-are-trading-higher-after-the-company-reported-better-than-expected-q2-financial-results-and-raised-its-fy24-revenue-guidance
Supernus Pharmaceuticals shares are tradin...
08/07/2024 14:44:22

supernus-raises-2024-total-revenue-guidance-from-580m-620m-to-600m-625m-vs-60012m-est
Supernus Raises 2024 Total Revenue Guidanc...
08/06/2024 20:21:31

supernus-pharmaceuticals-q2-2024-gaap-eps-036-beats-005-estimate-sales-168300m-beat-148851m-estimate
Supernus Pharmaceuticals Q2 2024 GAAP EPS ...
08/06/2024 20:14:29

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate...

supernus-resubmits-nda-to-fda-for-spn-830-apomorphine-infusion-device
Supernus Resubmits NDA To FDA For SPN-830 ...
08/01/2024 21:30:30

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products fo...

supernus-pharmaceuticals-announces-interim-analysis-data-from-phase-2a-clinical-study-of-spn-817-for-treatment-resistant-seizures
Supernus Pharmaceuticals Announces Interim...
05/23/2024 20:09:21

supernus-pharmaceuticals-reiterates-fy24-revenue-580m-620m-vs-601461m-est
Supernus Pharmaceuticals Reiterates FY24 R...
05/08/2024 21:25:29

supernus-pharmaceuticals-q1-sales-143600m-miss-145832m-estimate
Supernus Pharmaceuticals Q1 Sales $143.600...
05/08/2024 21:21:47

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly sales of $143.600 million which missed the analyst consensus estimate...

m8-pharmaceuticals-signs-an-exclusive-licensing-agreement-with-supernus-pharmaceuticals-to-seek-regulatory-approval-and-commercialize-qelbree-under-m8s-trademark-in-latin-america
M8 Pharmaceuticals Signs An Exclusive Lice...
05/07/2024 14:03:00

M8 Pharmaceuticals, an Acino company ('M8') announces that the company has signed an exclusive licensing agreement with...

supernus-pharmaceuticals-faces-second-fda-rejection-for-investigational-device-for-parkinsons-disease
Supernus Pharmaceuticals Faces Second FDA ...
04/08/2024 14:11:37

Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for ...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
04/08/2024 12:09:45

supernus-provides-regulatory-update-for-spn-830-fda-has-issued-a-crl-in-response-to-the-cos-nda-for-spn-830-indicating-that-the-review-cycle-for-the-application-is-complete-but-that-the-application-is-not-ready-for-approval-in-its-present-form
Supernus Provides Regulatory Update For SP...
04/08/2024 12:06:03

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products fo...

piper-sandler-maintains-overweight-on-supernus-pharmaceuticals-lowers-price-target-to-41
Piper Sandler Maintains Overweight on Supe...
02/28/2024 15:40:29

Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and lowers the price...

supernus-sees-fy24-total-revenue-580m-620m-vs-62252m-est
Supernus Sees FY24 Total Revenue $580M-$62...
02/27/2024 22:15:26

recap-supernus-pharmaceuticals-q4-earnings
Recap: Supernus Pharmaceuticals Q4 Earnings
02/27/2024 21:30:12

supernus-pharmaceuticals-q4-2023-adj-eps-039-misses-055-estimate-sales-16431m-beat-15503m-estimate
Supernus Pharmaceuticals Q4 2023 Adj EPS $...
02/27/2024 21:30:06

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.39 per share which missed the analyst consensus estima...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION